Skip to main navigation menu Skip to main content Skip to site footer

Relation neutrophils-lymphocytes in solid tumors.

Relación neutrófilos-linfocitos en tumores sólidos.




Section
Original articles

How to Cite
Relation neutrophils-lymphocytes in solid tumors.
Rev. colomb. hematol. oncol. [Internet]. 2020 Feb. 1 [cited 2024 Dec. 20];7(1):43-50. Disponible en: https://doi.org/10.51643/22562915.19

Dimensions
PlumX
Giovanny M. Caicedo
    Margarita Velasco
      Lisbeth P. Ramírez
        Luis F. Cárdenas

          Jorge I. López

          Especialista en Medicina Interna y Geriatría. Especialista en Epidemiología.


          Giovanny M. Caicedo,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Margarita Velasco,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Lisbeth P. Ramírez,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Luis F. Cárdenas,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Juan M. Herrera,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Eliana Ocampo Toro,

          Grupo de Investigación en Hematooncología (GIHO). Especialización en Hematología y Oncología Clínica, Universidad Libre Seccional Cali (Cali, Colombia).


          Álvaro J. Guerrero,

          Residente 2º año de especialización en Hematología y Oncología Clínica. Universidad Libre (Cali, Colombia).


          Background: The association between cancer and inflammation has aroused great interest in recent years. The neutrophil/ lymphocyte ratio (NLR) has been used as a prognostic value and clinical outcome in cancer. Objective: To determine the high NLR (>2.5) with the clinical stage, metastasis and other markers of severity in patients with solid tumors. Methods: Analytical cross-sectional study, including 170 clinical histories of patients with solid tumors, not exposed to chemotherapy, describing the clinical characteristics and the association of the NLR with the clinical stage, histological type, and degree of differentiation, molecular profile and metastasis. The analyzes were performed with logistic regression, Stata version 12.0. Results: 76% women, median of 63 years, breast cancer 61.1%, prostate 12.3%, colon 15.8%, lung 5.8% and ovary 4.7%. The NLR>2.5 was associated with advanced stage of disease (III and IV) OR: 6.38 (IC95% 1.67-24.4) p=0.007 and OR 4.6 (IC95% 1.13-19) p=0.033 respectively, poorly differentiated tumors OR 2.91 (IC95% 1.01-4.5) p = 0.046 and visceral metastasis OR=4.7 (IC95% 2.2-9.9) p=0.000. No association was found between the NLR and the histological type, molecular profile in breast cancer, Gleason scale in prostate cancer, or bone metastasis. Conclusions: Elevated neutrophil/lymphocyte radius was associated in this study with advanced stage of disease, poorly differentiated tumors and visceral metastasis. It is necessary to expand the sample in order to confirm these results, and in the future, perform studies that relate to therapeutic efficacy.


          Article visits 3533 | PDF visits 1895


          1. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophillymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88:218-30.
          2. Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets and Therapy. 2018;11:955-65.
          3. Granot Zvi, Jablonska J. Distinct functions of neutrophil in cancer and Its regulation. Mediators of Inflammation. 2015; 2015:701067.
          4. Dolan RD, Laird BJ, et al. The prognostic value of the systemic inflammatory response in randomised clinical trials in cancer: asystematic review. Clin Reviews Oncology/Hematology. 2018; 132:130-137.
          5. Templeton AJ, Namara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:124.
          6. Rossi S, et al. Are markers of systemic inflammation good prognostic indicators in colorectal cancer? Clinical Colorectal Cancer. 2017;16(4):264-74.
          7. Shitara K, Nishikawa H. Regulatory T cells: a potential target in cancer immunotherapy. Ann. N.Y. Acad. Sci. 2018;1417(1): 104-15.
          8. Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cáncer immunosuppression - implications for anticancer therapy. Nature Reviews Clinical Oncology. 2019;s41571.
          9. Ocaña A, Nieto-Jiménez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Molecular Cancer. 2017;16:137.
          10. Templeton AJ, McNamara M, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106 (6):1-11.
          11. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543-88.
          12. Kiriu T, Yamamoto M, et al. The Time-series behavior of neutrophil to lymphocyte ratio is useful as predictive marker in non small cell lung cancer. Plos One. 2018;13(2):1-13.
          13. Cedre´s S, Torrejon D, Martínez A, Martínez P, Navarro A, Zamora E, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clinical & Translational Oncology. 2012;14:864-9.
          14. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer. 2017;111:176-81.
          15. Stephanie Labomascus, et al. Neutrophil to lymphocyte ratio as predictive of prolonged progression free survival (PFS) and overall survival (OS) in patients with metastatic non-small cell lung cancer (NSCLC) treated with second-line PD-1 immune checkpoint inhibitors. Journal Of Clinical Oncology. 2017;35 (15): suppl.e14530.
          16. Zhao Z, Zhao X, et al. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analisis. Arch Gynecol Obstet. 2018; 297(4):849-57.
          17. Guthrie GJ, Charles K, et al. The systemic inflammationbased neutrophil–lymphocyte ratio: experience in patients with cancer. Critical Reviews in Oncology/Hematology. 2013;88:218-30.
          18. Yang F, Feng C, Zhang X, Lu J, Zhao Y. The diverse biological functions of neutrophils, beyond the defense against infections. Inflammation. 2016;40(1):311-23.
          19. Dolan RD, McSorley ST, et al. The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017;116:134-46.
          20. Estimated age-standardized incidence rates (World) in 2018, all cancers, both sexes, all ages. http://gco.iarc.fr. International Agency Research cancer. [En línea] Globocan, 2018. Disponible en: http://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=5&grou.
          21. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan, cancer incidence and mortality world wide: IARC Cancer Base. 2013;11:20.
          22. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Globocan, 2012, Cancer incidence and mortality world wide: IARC Cancer Base. 2013;11:20.
          23. Mu- Xing Li, Wue-Min Liu, et al. Prognostic role of neutrophilto-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J. Cancer.2014;134:2403-13.
          24. Zubing Mei, Lu Shi, et al. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. Cancer Tratment Reviews. 2017;58:1-13.
          25. Sebahattin Celik, M. Eyüp Yılmaz, Ethem Bilgiç. Analysis of the relationship between the levels of carcinoembryonic antigen and lactate dehydrogenase, and the neutrophil/lymphocyte ratio in colorectal cancer. Immunochem Immunopathol. 2016;2 (1):1000119.
          26. Azab B, Bhatt V, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19:217e24.
          27. Ethie JL, Desautels D, et al. Prognostic role of neutrophil-to ymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Research. 2017;19:2.
          28. Campbell SD, Donald C. McMillan. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology. 2010;6(1):149-63.
          29. Jong Jin Oh, Ohsung Kwon,et al. Association of the neutrophilto-lymphocyte ratio and prostate cancer detection rates in patients via contemporary multi-core prostate biopsy. Asian Journal of Andrology. 2016;18:937-41.
          30. Lu Tang, Xintao Li, Baojun Wang, et al. Prognostic value of neutrophil-to lymphocyte ratio in localized and advanced prostate cancer: a systematic review and meta-analysis. PLOS one. 2016; 11(4):e0153981.
          31. Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta-analysis. Clinics (Sao Paulo). 2015;70(7):524-30.
          32. Williams KA, Labidi-Galy SI, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014;132(3):542-50.
          33. Faria SS, Fernandes PC, et al. The neutrophil-to-lymphocyte ratio: a narrative review. ecancer Medical Science. 2016;10:702.
          34. Huang TB, et al. Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy A Strobe-compliant study. Medicine. 2016;95:44.
          35. Serdarevic M, et al. Could neutrophil-to-lymphocyte ratio be predictor of brain metastases in non small cell lung cancer? Abstracts, ELLCC. 2016;S145.
          36. Zhen SW, Fang F, et al. The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metástasis. Oncol Lett. 2011;2(4):735-40.
          37. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. British Journal of Cancer. 2012; 107(4):695-9.
          38. Neal RD, Tharmanathan P, France B, et al. ¿El aumento del tiempo para el diagnóstico y tratamiento en el cáncer sintomático se asocia con resultados más pobres? Revisión sistemática. Br J Cancer. 2015;112(1):92-107.
          Sistema OJS 3.4.0.7 - Metabiblioteca |